Regenerative medicine company AVITA Medical (AVH) has appointed James Corbett as CEO, effective immediately.
Mr Corbett has almost 40 years of experience in the life sciences field and has extensive global, operational and commercial experience.
He has previously been CEO of publicly traded companies Microtherapeutics, ev3 Inc and Alphatec Spine, and private companies Home Diagnostics Inc, Vertos Medical Inc and CathWorks.
“Jim is an experienced strategist with significant commercial expertise that positions him well to lead AVITA Medical through its next stage of growth and beyond,” Chairman Lou Panaccio said.
“Having run a thorough process utilising a leading executive search firm, I am confident that Jim is the right leader for the company at this time.”
Mr Corbett will be replacing Dr Michael Perry who served as CEO and Executive Director since June 2017.
“We are grateful to Dr Perry for his many contributions to AVITA Medical. We thank him for his commitment to AVITA Medical, its customers, employees, shareholders, and thepatients we serve,” Dr Panaccio concluded.
AVITA was up 3.12 per cent on the market with shares trading at $1.74 at 1:28 pm AEST.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.